CCT2 is an aggrephagy receptor for clearance of solid protein aggregates
- PMID: 35366418
- DOI: 10.1016/j.cell.2022.03.005
CCT2 is an aggrephagy receptor for clearance of solid protein aggregates
Abstract
Protein aggregation is a hallmark of multiple human pathologies. Autophagy selectively degrades protein aggregates via aggrephagy. How selectivity is achieved has been elusive. Here, we identify the chaperonin subunit CCT2 as an autophagy receptor regulating the clearance of aggregation-prone proteins in the cell and the mouse brain. CCT2 associates with aggregation-prone proteins independent of cargo ubiquitination and interacts with autophagosome marker ATG8s through a non-classical VLIR motif. In addition, CCT2 regulates aggrephagy independently of the ubiquitin-binding receptors (P62, NBR1, and TAX1BP1) or chaperone-mediated autophagy. Unlike P62, NBR1, and TAX1BP1, which facilitate the clearance of protein condensates with liquidity, CCT2 specifically promotes the autophagic degradation of protein aggregates with little liquidity (solid aggregates). Furthermore, aggregation-prone protein accumulation induces the functional switch of CCT2 from a chaperone subunit to an autophagy receptor by promoting CCT2 monomer formation, which exposes the VLIR to ATG8s interaction and, therefore, enables the autophagic function.
Keywords: CCT2; FUS; GABARAP; Huntington’s disease; LC3; NBR1; P62; SOD1; TAX1BP1; TRiC; aggrephagy; autophagy; chaperone; chaperonin; huntingtin; neurodegeneration; phase separation; protein aggregates; protein aggregation; tau.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests L.G., M. Zhang, X.M., C.L., S.L., and X.T. are inventors on a patent application that covers the use of the chaperones reported in the manuscript as potential therapeutic strategies against human diseases caused by protein aggregation. The other authors declare no commercial or financial conflicts of interest.
Comment in
-
Chaperoning solid aggregates for autophagy.Nat Rev Mol Cell Biol. 2022 Jun;23(6):387. doi: 10.1038/s41580-022-00482-x. Nat Rev Mol Cell Biol. 2022. PMID: 35383338 No abstract available.
-
Only solid waste, please!Mol Cell. 2022 Apr 21;82(8):1408-1410. doi: 10.1016/j.molcel.2022.04.003. Mol Cell. 2022. PMID: 35452612
-
Chaperonin-containing TCP-1 subunit 2-mediated aggrephagy: A potential target for treating neurodegeneration.Clin Transl Med. 2022 Aug;12(8):e1027. doi: 10.1002/ctm2.1027. Clin Transl Med. 2022. PMID: 35988155 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
